213 related articles for article (PubMed ID: 23436301)
1. Induction mortality and resource utilization in children treated for acute myeloid leukemia at free-standing pediatric hospitals in the United States.
Kavcic M; Fisher BT; Li Y; Seif AE; Torp K; Walker DM; Huang YS; Lee GE; Tasian SK; Vujkovic M; Bagatell R; Aplenc R
Cancer; 2013 May; 119(10):1916-23. PubMed ID: 23436301
[TBL] [Abstract][Full Text] [Related]
2. Intensively timed combination chemotherapy for the induction of adult patients with acute myeloid leukemia: long-term follow-up of a phase 2 study.
Rytting M; Ravandi F; Estey E; Cortes J; Faderl S; Garcia-Manero G; Jeha S; Ouzounian S; Pierce S; Kantarjian H
Cancer; 2010 Nov; 116(22):5272-8. PubMed ID: 20665501
[TBL] [Abstract][Full Text] [Related]
3. Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: a report from the Children's Cancer Group.
Woods WG; Kobrinsky N; Buckley JD; Lee JW; Sanders J; Neudorf S; Gold S; Barnard DR; DeSwarte J; Dusenbery K; Kalousek D; Arthur DC; Lange BJ
Blood; 1996 Jun; 87(12):4979-89. PubMed ID: 8652810
[TBL] [Abstract][Full Text] [Related]
4. Outpatient ADE (cytarabine, daunorubicin, and etoposide) is feasible and effective for the first relapse of pediatric acute myeloid leukemia: A prospective, phase II study.
Garg A; Ganguly S; Vishnubhatla S; Chopra A; Bakhshi S
Pediatr Blood Cancer; 2020 Sep; 67(9):e28404. PubMed ID: 32672904
[TBL] [Abstract][Full Text] [Related]
5. The role of acuity of illness at presentation in early mortality in black children with acute myeloid leukemia.
Winestone LE; Getz KD; Miller TP; Wilkes JJ; Sack L; Li Y; Huang YS; Seif AE; Bagatell R; Fisher BT; Epstein AJ; Aplenc R
Am J Hematol; 2017 Feb; 92(2):141-148. PubMed ID: 27862214
[TBL] [Abstract][Full Text] [Related]
6. Favorable survival maintained in children who have myeloid leukemia associated with Down syndrome using reduced-dose chemotherapy on Children's Oncology Group trial A2971: a report from the Children's Oncology Group.
Sorrell AD; Alonzo TA; Hilden JM; Gerbing RB; Loew TW; Hathaway L; Barnard D; Taub JW; Ravindranath Y; Smith FO; Arceci RJ; Woods WG; Gamis AS
Cancer; 2012 Oct; 118(19):4806-14. PubMed ID: 22392565
[TBL] [Abstract][Full Text] [Related]
7. Decreased relapsed rate and treatment-related mortality contribute to improved outcomes for pediatric acute myeloid leukemia in successive clinical trials.
Alexander TB; Wang L; Inaba H; Triplett BM; Pounds S; Ribeiro RC; Pui CH; Rubnitz JE
Cancer; 2017 Oct; 123(19):3791-3798. PubMed ID: 28556917
[TBL] [Abstract][Full Text] [Related]
8. Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia. Results of the Medical Research Council's 10th AML trial (MRC AML10). Adult and Childhood Leukaemia Working Parties of the Medical Research Council.
Hann IM; Stevens RF; Goldstone AH; Rees JK; Wheatley K; Gray RG; Burnett AK
Blood; 1997 Apr; 89(7):2311-8. PubMed ID: 9116274
[TBL] [Abstract][Full Text] [Related]
9. Posterior reversible encephalopathy syndrome (PRES) during induction chemotherapy for acute myeloblastic leukemia (AML).
Battipaglia G; Avilia S; Morelli E; Caranci F; Perna F; Camera A
Ann Hematol; 2012 Aug; 91(8):1327-8. PubMed ID: 22237936
[No Abstract] [Full Text] [Related]
10. Etoposide in remission induction of adult acute myeloid leukemia.
Leoni F; Ciolli S; Patriarchi S; Morfini M; Rossi Ferrini P
Acta Haematol; 1990; 83(2):82-5. PubMed ID: 2106200
[TBL] [Abstract][Full Text] [Related]
11. Improved outcome in childhood acute myeloid leukemia in Singapore with the MRC AML 10 protocol.
Tan RM; Quah TC; Aung L; Liang S; Kirk RC; Yeoh AE
Pediatr Blood Cancer; 2007 Mar; 48(3):262-7. PubMed ID: 16602120
[TBL] [Abstract][Full Text] [Related]
12. Intensive timed sequential remission induction chemotherapy with high-dose cytarabine for childhood acute myeloid leukemia.
Loeb DM; Bowers DC; Civin CI; Friedman AD
Med Pediatr Oncol; 2001 Oct; 37(4):365-71. PubMed ID: 11568900
[TBL] [Abstract][Full Text] [Related]
13. Treatment of acute myelogenous leukemia in patients over 50 years of age with V-TAD: a Southwest Oncology Group study.
Bigelow CL; Kopecky K; Files JC; Head D; Lipschitz DA; Grever M; Appelbaum FR
Am J Hematol; 1995 Apr; 48(4):228-32. PubMed ID: 7717369
[TBL] [Abstract][Full Text] [Related]
14. Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: results of Study Acute Myeloid Leukemia-Berlin-Frankfurt-Münster 93.
Creutzig U; Ritter J; Zimmermann M; Reinhardt D; Hermann J; Berthold F; Henze G; Jürgens H; Kabisch H; Havers W; Reiter A; Kluba U; Niggli F; Gadner H
J Clin Oncol; 2001 May; 19(10):2705-13. PubMed ID: 11352963
[TBL] [Abstract][Full Text] [Related]
15. Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502.
Attar EC; Johnson JL; Amrein PC; Lozanski G; Wadleigh M; DeAngelo DJ; Kolitz JE; Powell BL; Voorhees P; Wang ES; Blum W; Stone RM; Marcucci G; Bloomfield CD; Moser B; Larson RA
J Clin Oncol; 2013 Mar; 31(7):923-9. PubMed ID: 23129738
[TBL] [Abstract][Full Text] [Related]
16. A multicenter, randomized study of decitabine as epigenetic priming with induction chemotherapy in children with AML.
Gore L; Triche TJ; Farrar JE; Wai D; Legendre C; Gooden GC; Liang WS; Carpten J; Lee D; Alvaro F; Macy ME; Arndt C; Barnette P; Cooper T; Martin L; Narendran A; Pollard J; Meshinchi S; Boklan J; Arceci RJ; Salhia B
Clin Epigenetics; 2017; 9():108. PubMed ID: 29034009
[TBL] [Abstract][Full Text] [Related]
17. [Improved treatment results in children with AML: Results of study AML-BFM 93].
Creutzig U; Berthold F; Boos J; Fleischhack G; Gadner H; Gnekow A; Graubner U; Henze G; Hermann J; Imbach P; Jürgens H; Kabisch H; Körholz D; Niemeyer CM; Reinhardt D; Reiter A; Ritter J; Spaar HJ; Zimmermann M;
Klin Padiatr; 2001; 213(4):175-85. PubMed ID: 11528551
[TBL] [Abstract][Full Text] [Related]
18. The outcome and prognostic factors of 248 elderly patients with acute myeloid leukemia treated with standard-dose or low-intensity induction therapy.
Chen Y; Yang T; Zheng X; Yang X; Zheng Z; Zheng J; Liu T; Hu J
Medicine (Baltimore); 2016 Jul; 95(30):e4182. PubMed ID: 27472687
[TBL] [Abstract][Full Text] [Related]
19. Oral induction and consolidation of acute myeloid leukemia with etoposide, 6-thioguanine, and idarubicin (ETI) in elderly patients: a randomized comparison with 5-day TAD. Finnish Leukemia Group.
Ruutu T; Almqvist A; Hallman H; Honkanen T; Järvenpää E; Järventie G; Koistinen P; Koivunen E; Lahtinen R; Lehtinen M
Leukemia; 1994 Jan; 8(1):11-5. PubMed ID: 8289475
[TBL] [Abstract][Full Text] [Related]
20. Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial.
Rubnitz JE; Inaba H; Dahl G; Ribeiro RC; Bowman WP; Taub J; Pounds S; Razzouk BI; Lacayo NJ; Cao X; Meshinchi S; Degar B; Airewele G; Raimondi SC; Onciu M; Coustan-Smith E; Downing JR; Leung W; Pui CH; Campana D
Lancet Oncol; 2010 Jun; 11(6):543-52. PubMed ID: 20451454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
